本次电话会议仅服务于华创证券研究所客户不构成投资建议相关人员应自主做出投资决策并自行承担投资风险 华创证券不应使用本次内容所导致的任何损失承担任何责任专家发言内容仅代表专家个人观点不代表本公司观点本次会议内容不得涉及国家保密信息内幕信息未公开重大信息商业秘密个人隐私不得涉及可能引发不当炒作或股价异常波动的敏感信息 不得涉及影响社会或资本市场稳定的言论未经华创证券事先书面许可任何机构或个人不得以任何形式复制、刊载、转载、转发引用本次会议内容否则由此造成的一切后果及法律责任由该机构或个人承担本公司保留追究其法律责任的权利市场有风险投资需谨慎 各位投资者大家晚上好我是华创医药的万慕迪接下来由我来给大家汇报一下我们对于太阁的观点首先我们一起来复盘一下太阁的一个过去发展历程我们也是分成了四个按照时间轴分成了四个阶段首先第一个方面是04到08年 那在这个阶段呢其实整个国内的这个CIO行业是才逐渐兴起啊就21世纪初的时候那泰格也是04年成立并且以这个临床实验技术服务起家那泰格自成立起就非常重视质量这一块也是参照了罗氏的SOP然后遵循没有记录就没有发生的这种临床监察标准去逐步推进临床实验 同时公司也不断的去建设国内的网络渠道 ...

公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）近日接到公司持股5%以上股东曹 晓春女士通知，获悉曹晓春女士办理其持有的部分股份被质押以及部分股份回购并解除质 押业务，具体内容如下： 证券代码：300347 证券简称：泰格医药 公告编码（2024）034 号 杭州泰格医药科技股份有限公司 关于持股 5%以上股东新增质押及部分股份回购并解除质押的公告 特此公告。 1、中国证券登记结算有限责任公司出具的《证券质押及司法冻结明细表》。 一、 质押变动的基本情况 | 股东名 | 是否为控 股股东或 第一大股 | 本次质押 数量 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否为 补充质 | 质押起始 | 质押到期 | 质权人 | 质押用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | | | | | 限售股 | | 日 | 日 | | | | | 东及其一 | （股） | 比例 | 比例 | | ...

证券代码：300347 证券简称：泰格医药 公告编码（2024）033 号 杭州泰格医药科技股份有限公司 关于回购股份注销完成暨股份变动的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述 或者重大遗漏负连带责任。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购股份注 销事宜已于 2024 年 5 月 10 日办理完成。 杭州泰格医药科技股份有限公司（以下简称"公司"）分别于 2024 年 3 月 28 日、 2024 年 4 月 30 日召开第五届董事会第六次会议、第五届监事会第四次会议、2024 年 第二次临时股东大会、2024 年第一次 A 股类别股东会议及 2024 年第一次 H 股类别股 东会议，审议通过《关于注销回购股份并减少公司注册资本的议案》，公司拟注销存放 于公司回购专用证券账户的 7,469,650 股股份，并相应减少公司注册资本。具体情况公 告如下： 一、回购股份的基本情况 特别提示： 1、本次注销的回购股份数量为 7,469,650 股，占注销前公司总股本的 0.86%。本 次 注销完成后，公司总股本将由 872,418,220 ...

Investment Rating - The report assigns a "Recommended" rating to the company, with a target price of 75 yuan based on a discounted cash flow valuation method, resulting in an overall valuation of 650 billion yuan [2][9]. Core Insights - The company is positioned as a leading domestic clinical CRO, expected to benefit significantly from the industry's transition towards both volume and price increases. The improving overseas investment environment and the growing number of foreign pharmaceutical companies conducting clinical trials in China are key factors driving this growth [2][8]. - The company has a robust competitive edge, covering the entire R&D value chain and providing integrated research solutions, supported by extensive project experience and a loyal customer base [2][8]. Summary by Sections Company Overview - The company has developed a strong competitive position through comprehensive development capabilities, global operational management, and a wide network of collaborations with research institutions [2][8]. - The core business is clinical trial technical services, with significant growth potential in related services and laboratory services, creating a high barrier to entry through business synergy [2][8]. Industry Outlook - The domestic pharmaceutical market is improving, with a stable recovery in the investment environment. The demand for innovative drugs is increasing, supported by favorable domestic policies [2][8]. - The company is well-positioned to act as a bridge between the Chinese and global clinical research markets, with opportunities in four key market segments: domestic clinical trials for local companies, overseas clinical trials for local companies, domestic clinical trials for foreign companies, and overseas clinical trials for foreign companies [2][8]. Financial Projections - Revenue projections for 2024, 2025, and 2026 are 83.2 billion yuan, 94.3 billion yuan, and 107.5 billion yuan, respectively, with year-on-year growth rates of 12.7%, 13.4%, and 14.0% [2][9]. - Net profit forecasts for the same years are 17.05 billion yuan, 20.18 billion yuan, and 24.26 billion yuan, with changes of -15.8%, +18.3%, and +20.2% respectively [2][9].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2024年4月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2024年5月6日 I. 法定/註冊股本變動 FF301 第 1 頁 共 6 頁 v 1.0.2 FF301 II. 已發行股份變動 | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 (註1) | 否 | | --- | --- | --- | --- | --- | --- | | 證券代號 | 300347 | 說明 | 於深圳證券交易所上市 | | | | 上月底結存 | | 749,293,420 | | | | | 增加 / 減少 (-) | | | 0 | | | | 本月底結存 | | 749,293,420 | | | | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...

Financial Performance - In 2023, the company's revenue increased to RMB 7,384.0 million, a year-on-year growth of 4.2% from RMB 7,085.5 million in 2022[5] - Adjusted net profit attributable to shareholders reached RMB 1,786.0 million, reflecting a year-on-year increase of 7.2%[5] - The gross profit for 2023 was RMB 2,820.6 million, a 1.3% increase compared to RMB 2,785.4 million in the previous year[12] - The net profit attributable to the company's owners was RMB 2,026.5 million, showing a slight increase of 0.5% from RMB 2,016.1 million in 2022[12] - The adjusted net profit attributable to the company's owners was RMB 1,786.0 million, reflecting a 7.2% increase from RMB 1,665.8 million in 2022[12] - The total order amount for 2023 was RMB 7,852 million, a decline of 18.8% compared to the previous year, primarily due to order cancellations and a significant drop in handling fees[23] - The company's backlog as of December 31, 2023, was RMB 14,080 million, reflecting a year-on-year increase of 2.1%[23] - The net profit for the year decreased by 5.7% to RMB 2,151.6 million, mainly due to increased sales costs and marketing expenses[62] - The effective tax rate rose from 12.1% to 13.6%, influenced by changes in certain other income items that were not fully taxable[61] Revenue Sources - Revenue from clinical trial technical services amounted to RMB 4,168.1 million, with a year-on-year growth of 1.0%[5] - Revenue from clinical trial-related services and laboratory services reached RMB 3,215.9 million, showing a year-on-year increase of 8.6%[5] - Clinical trial-related services and laboratory services generated revenue of RMB 3,215.9 million, an increase of 8.6% from RMB 2,960.3 million in the same period last year[40] Market Position and Growth - The company maintained its market leadership in China's clinical CRO industry, servicing 22 Class 1 new drugs and 6 innovative medical devices in 2023[5] - Cumulatively, the company has provided services for 61% of China's listed Class 1 new drug developments since its establishment in 2004[5] - The company is optimistic about the post-pandemic "new normal" and expects improvements in the industry environment in 2024[19][21] - The company continues to maintain its leading position in China's clinical contract research organization industry despite challenges from the COVID-19 vaccine revenue decline[23] - The company has achieved a market share of 61% in providing services for newly listed Class I drugs in China from 2004 to 2023[100] International Expansion - The company established an international headquarters in Hong Kong in 2023, expanding its global operational footprint to 28 countries with 1,632 overseas employees[6] - The company expanded its international operations, opening an international headquarters in Hong Kong and significantly increasing clinical trial service revenue in the U.S.[26] - The company has formed strategic alliances with 52 clinical trial excellence centers, establishing 224 core cooperation centers nationwide by December 31, 2023[101] Employee and Operational Growth - The company has over 9,000 employees contributing to its robust growth and resilience in a challenging environment[5] - The total number of employees increased to 9,701 as of December 31, 2023, up from 9,455 as of June 30, 2023, reflecting a growth strategy in key overseas markets[50] - The number of ongoing drug clinical research projects rose from 680 as of December 31, 2022, to 752 as of December 31, 2023[31] - The number of clients served by the registration team increased from 649 to 720, completing 1,009 project experiences, and assisting 9 products in obtaining approval in China in 2023[35] Research and Development - The company is advancing its three major development strategies: globalization, integration, and digitization[4] - The company plans to enhance its integrated R&D service platform and expand its global market share through acquisitions and partnerships with multinational pharmaceutical companies[22] - The company has established integrated R&D service platforms for pharmaceuticals and medical devices, covering the entire lifecycle from drug discovery to post-market studies[98] Financial Health and Investments - The total assets of the company as of December 31, 2023, were RMB 29,680.7 million, an 8.1% increase from RMB 27,446.5 million in 2022[13] - The company's cash and cash equivalents decreased by 4.9% to RMB 7,399.9 million from RMB 7,782.7 million in 2022[13] - The company realized gains of RMB 546.1 million from exits in investments during the reporting period, significantly higher than RMB 162.8 million in the same period last year[82] - The company is a strategic investor in 170 innovative companies in the healthcare sector and a limited partner in 55 professional investment funds as of December 31, 2023[81] Risks and Challenges - The company faces potential risks from natural disasters, pandemics, and other emergencies that could adversely affect its operations, financial condition, and performance[115] - A decline in demand for biopharmaceutical research services could significantly impact the company's business, financial condition, and performance if trends in the pharmaceutical market reverse[116] - Increased competition in the global clinical contract research organization market may lead to pricing pressure, affecting the company's revenue and profitability[117] - The company anticipates continued business growth, necessitating effective management of expansion strategies to avoid adverse impacts on its financial condition and performance[117] Corporate Governance - The company has a strong governance structure with independent directors overseeing financial and operational matters[143] - The board consists of seven members, including four executive directors and three independent non-executive directors, ensuring effective governance[154] - The company has adopted corporate governance practices in line with the principles outlined in the listing rules, maintaining high standards of governance[150] - The company emphasizes the importance of good corporate governance in enhancing management and protecting shareholder interests[150] Environmental, Social, and Governance (ESG) Initiatives - The company received an AAA rating from the Shenzhen Stock Exchange for its ESG governance and improved its MSCI ESG rating to AA[10] - The company published the "Tigermed ESG Guidelines," covering anti-corruption, employee rights, customer rights, environmental protection, and social welfare[190] - The company is committed to improving its ESG performance, with specific short-term and long-term improvement goals outlined[191]

2024 年 4 月 29 日 CMB 国际全球市场 | 股票研究 | 公司更新 泰格迈德 (300347 CH) 第 1 季度有意义的需求复苏 目标价格 66.82 元 Tigermed 报告第 1 季度收入为 16.6 亿元人民币 ， 同比下降 8.0 ％ ， 可归属经常性净收入 （ 以前的 TP 为 68.57 元人民币 ） 为 3.03 亿元人民币 ， 同比下降 20.5 ％ ， 这主要是由于公允价值变动和投资变动的收益大 涨 / 跌 15.8% 幅减少 （ 第 1 季度为 800 万元人民币 ， 第 1 季度为 1.98 亿元人民币 ） 。 1 季度 24 收入 现价人民币 57.70 元中国医疗保健 / 可归属经常性净收入分别占我们 2024 年全年估计的 19.8% / 18.0%，与 COVID 前的平均水 平基本一致。如果不包括 COVID 疫苗相关收入，第 1 季度的收入将与第 1 季度持平。在持续 Jill Wu, CFA 的成本管理措施以及实验室服务的 MoM GPM 改进的推动下，第 1 季度的毛利率 （ GPM ） (852) 3900 0842 为 37.8 ％，季度环比显着提高 ...

M N 29 Apr 2024 CMB International Global Markets | Equity Research | Company Update Tigermed (300347 CH) Meaningful demand recovery in 1Q24 Target Price RMB66.82 Tigermed reported 1Q24 revenue of RMB1,660mn, down 8.0% YoY, and (Previous TP RMB68.57) attributable recurring net income of RMB303mn, down 20.5% YoY, which was Up/Downside 15.8% mainly due to the substantially reduced gains on fair value changes and Current Price RMB57.70 investment changes (RMB8mn in 1Q24 vs RMB198mn in 1Q23). 1Q24 revenue / attr ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][6] Core Views - The company is experiencing a temporary performance pressure, but is expected to gradually recover in 2024. The decline in performance is primarily due to reduced COVID-related business and fluctuations in downstream market demand. However, the company has a solid order backlog, with a total contract amount of 14.08 billion yuan as of the end of 2023, representing a year-on-year growth of 2.1%, which supports stable growth in 2024 [6][7] - The company is recognized as a leading clinical CRO in China, with strong competitiveness and steady development in statistical and SMO (Site Management Organization) businesses. The projected net profits for 2024-2026 are 2.24 billion, 2.49 billion, and 2.82 billion yuan, respectively, with corresponding EPS of 2.57, 2.85, and 3.23 yuan [6][8] Financial Performance Summary - In Q1 2024, the company achieved operating revenue of 1.66 billion yuan, a year-on-year decline of 8.0%. The net profit attributable to the parent company was 235 million yuan, down 58.65% year-on-year, while the net profit after deducting non-recurring gains and losses was 303 million yuan, down 20.50% year-on-year [6] - The clinical trial technical services segment generated revenue of 4.168 billion yuan in 2023, reflecting a year-on-year growth of 1.04%. The number of ongoing drug clinical research projects reached 752, an increase of 72 projects year-on-year [7] - The statistical and SMO businesses also showed steady growth, with the number of global clients in the statistical business reaching 340, a year-on-year increase of 31.27%. The number of SMO projects increased from 1,621 at the end of 2022 to 1,952 [8] Financial Forecast Summary - The company's projected financial metrics for 2024-2026 include: - Operating revenue: 8.195 billion yuan (2024E), 9.194 billion yuan (2025E), 10.526 billion yuan (2026E) - Net profit attributable to the parent company: 2.24 billion yuan (2024E), 2.49 billion yuan (2025E), 2.82 billion yuan (2026E) - EPS: 2.57 yuan (2024E), 2.85 yuan (2025E), 3.23 yuan (2026E) - P/E ratios: 22.5 (2024E), 20.2 (2025E), 17.9 (2026E) [9][10]

Investment Rating - Buy rating maintained for Tigermed (300347 SZ) [2] Core Views - Multiple factors impacted Q1 performance, but recovery is expected as innovative drug policies take effect [2] - Vaccine project base effects and investment fluctuations affected Q1 results [4] - Favorable policies for innovative drugs in Beijing and Guangzhou are expected to drive business recovery [4] - Gross margin showed sequential improvement in Q1 2024, reaching 37 83% (up 5 01pp QoQ) [4] - Operating cash flow rebounded sharply in Q1 2024, reaching 144 million yuan (+405 84% YoY) [4] Financial Performance - Q1 2024 revenue was 1 66 billion yuan, down 8 00% YoY [4] - Q1 2024 net profit attributable to shareholders was 235 million yuan, down 58 65% YoY [4] - 2024-2026 revenue forecast: 8 55 billion, 10 30 billion, and 12 83 billion yuan, with YoY growth of 15 80%, 20 50%, and 24 49% respectively [5] - 2024-2026 net profit forecast: 2 30 billion, 2 73 billion, and 3 44 billion yuan, with YoY growth of 13 52%, 18 86%, and 25 82% respectively [5] Valuation Metrics - 2024-2026 EPS forecast: 2 63, 3 13, and 3 94 yuan [5] - 2024-2026 P/E ratios: 21 90x, 18 43x, and 14 64x [5] - 2024-2026 P/B ratios: 2 13x, 1 91x, and 1 69x [5] Industry Position - Tigermed is a leading domestic clinical CRO company with significant competitive advantages [5] - The company's global layout is taking shape, though overseas business integration faces challenges [13]